Contact
searchSearch
HMP Global
Login

Psych Congress Network

Latest News, Insights, and Quizzes

an illustrated laptop screen displaying a quiz
Quiz
Patient Priorities in MDD Treatment
07/13/2026
Maria Mantas
Can you recall which symptom of MDD patients most wanted to see improved by treatment? Take the quiz!
Can you recall which symptom of MDD patients most wanted to see improved by treatment? Take the quiz!
Can you recall which symptom of...
07/13/2026
Psych Congress Network
an illustration of a man sitting on the ground holding his head with his profile and brain in the background
Research Summary
iTBS Offers Short-Term Improvement in Major Depressive Disorder
07/10/2026
Brionna Mendoza
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial found that 10 once-daily sessions of iTBS produced short-term improvement compared to sham in clinician-rated depressive symptoms among adults with recurrent major depressive disorder (MDD).
A randomized clinical trial...
07/10/2026
Psych Congress Network
Kristian Dambrino, DNP, PMHNP-BC
Videos
Knowing When to Initiate Treatment for TD
07/07/2026
Kristian Dambrino, DNP, PMHNP, MSN
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair...
07/07/2026
Psych Congress Network
Craig Chepke and Kevin Williams
Major Depressive Disorder Insights
Anhedonia in MDD: What to Ask When Visit Time Is Short
07/07/2026
Craig Chepke, MD, DFAPA; Kevin Williams, MS, MPAS, PA-C
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how busy outpatient clinicians can effectively screen for anhedonia in major depressive disorder.
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how busy outpatient clinicians can effectively screen for anhedonia in major depressive disorder.
Craig Chepke, MD, DFAPA, and...
07/07/2026
Psych Congress Network
pills spilling out of a tipped over pill bottle
News
US Veterans Study Links SGLT2 Inhibitors to Lower Dementia Risk in Older Adults With Psychiatric Disorders
07/01/2026
Maria Mantas
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with a lower risk of incident all-cause dementia among older US veterans with mood and psychotic disorders. 
Sodium-glucose cotransporter 2...
07/01/2026
Psych Congress Network
A patient sits across from a doctor who has a clipboard and is filling out a phone
Research Summary
Single-Dose LSD Formulation Hits Primary Endpoint in Phase 3 MDD Trial
06/29/2026
Brionna Mendoza
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation of lysergide (LSD) for treatment of MDD, met both primary and key secondary endpoints in the phase 3 Emerge study.
DT120, a proprietary formulation...
06/29/2026
Psych Congress Network
a young woman lies awake in bed
News
Adolescent Insomnia and Daytime Sleepiness Linked to Depression Risk
06/25/2026
Maria Mantas
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression. 
A 3-year longitudinal study found that insomnia, excessive daytime sleepiness (EDS), and their co-occurrence were associated with increased risk of depression. 
A 3-year longitudinal study...
06/25/2026
Psych Congress Network
A man with depression holds his head in his hands
Research Summary
Navacaprant Fails Late-Stage MDD Trials
06/22/2026
Brionna Mendoza
Navacaprant, a kappa opioid receptor antagonist for major depressive disorder treatment, failed to show statistically significant efficacy in two phase 3 trials.
Navacaprant, a kappa opioid receptor antagonist for major depressive disorder treatment, failed to show statistically significant efficacy in two phase 3 trials.
Navacaprant, a kappa opioid...
06/22/2026
Psych Congress Network
a man surrounded by alcohol and other substances on a table
News
Reduced Stimulant Use Outcomes May Reveal Treatment Effects Missed by Abstinence Measures
06/18/2026
Maria Mantas
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
Evaluating reduced stimulant use rather than complete abstinence outcomes in patients with stimulant use disorder could provide additional insight into treatment efficacy.
Evaluating reduced stimulant use...
06/18/2026
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Psilocybin Outcomes for MDD
06/11/2026
Brionna Mendoza
Test your knowledge of recent research with this quiz!
Test your knowledge of recent research with this quiz!
Test your knowledge of recent...
06/11/2026
Psych Congress Network
FDA building
FDA Alerts
FDA Clears Personalized Neuromodulation System for PTSD Treatment
06/11/2026
Maria Mantas
The US Food and Drug Administration (FDA) has cleared Wave Neuroscience’s Magnetic EEG-guided Resonance Therapy (MeRT) System, a biomarker-guided neuromodulation technology for the treatment of posttraumatic stress disorder (PTSD).
The US Food and Drug Administration (FDA) has cleared Wave Neuroscience’s Magnetic EEG-guided Resonance Therapy (MeRT) System, a biomarker-guided neuromodulation technology for the treatment of posttraumatic stress disorder (PTSD).
The US Food and Drug...
06/11/2026
Psych Congress Network

Latest Expert Insights

Kristian Dambrino, DNP, PMHNP-BC
Videos
Knowing When to Initiate Treatment for TD
07/07/2026
Kristian Dambrino, DNP, PMHNP, MSN
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair...
07/07/2026
Psych Congress Network
Kristian Dambrino, DNP, PMHNP-BC
Videos
Knowing When to Initiate Treatment for TD
07/07/2026
Kristian Dambrino, DNP, PMHNP, MSN
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair Kristian Dambrino, DNP, PMHNP-BC, discusses practical considerations for pinpointing whether and when to begin targeted treatment for tardive dyskinesia (TD).
Psych Congress Elevate Co-Chair...
07/07/2026
Psych Congress Network
Craig Chepke and Kevin Williams
Major Depressive Disorder Insights
Anhedonia in MDD: What to Ask When Visit Time Is Short
07/07/2026
Craig Chepke, MD, DFAPA; Kevin Williams, MS, MPAS, PA-C
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how busy outpatient clinicians can effectively screen for anhedonia in major depressive disorder.
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how busy outpatient clinicians can effectively screen for anhedonia in major depressive disorder.
Craig Chepke, MD, DFAPA, and...
07/07/2026
Psych Congress Network
B. Nilaja Green, PhD
Q&As
Strengthening Interdisciplinary Collaboration in Mental Health Treatment
06/05/2026
B. Nilaja Green, PhD
B. Nilaja Green, PhD, reviews how psychiatric providers and psychotherapists can ensure they are aligned on patient treatment progress and goals.
B. Nilaja Green, PhD, reviews how psychiatric providers and psychotherapists can ensure they are aligned on patient treatment progress and goals.
B. Nilaja Green, PhD, reviews...
06/05/2026
Psych Congress Network
Veronica Ridpath, DO
Q&A
Advancing Autism Care in Psychiatric Practice
06/05/2026
Veronica Ridpath, DO
Veronica Ridpath, DO. discusses key considerations for diagnosing and supporting patients with autism spectrum disorder (ASD) in psychiatric practice.
Veronica Ridpath, DO. discusses key considerations for diagnosing and supporting patients with autism spectrum disorder (ASD) in psychiatric practice.
Veronica Ridpath, DO. discusses...
06/05/2026
Psych Congress Network
Jain, Mattingly, and Raison
Rapid Reaction
Rapid Reactions: Psych Congress Faculty Respond to HHS Deprescribing Initiative
05/12/2026
Rakesh Jain, MD, MPH, RD; Greg Mattingly, MD; Charles L. Raison, MD
Psych Congress faculty members share their expert perspectives on the HHS deprescribing action plan and Dear Colleague letter.
Psych Congress faculty members share their expert perspectives on the HHS deprescribing action plan and Dear Colleague letter.
Psych Congress faculty members...
05/12/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Treating Beyond AIMS Scores: Tracking Functional Outcomes in Tardive Dyskinesia
05/12/2026
Craig Chepke, MD, DFAPA
In this video, Craig Chepke, MD, DFAPA, Chief Medical Officer, Psych Congress, discusses the pitfalls of evaluating tardive dyskinesia (TD) treatment progress by an Abnormal Involuntary Movement Scale (AIMS) score alone.
In this video, Craig Chepke, MD, DFAPA, Chief Medical Officer, Psych Congress, discusses the pitfalls of evaluating tardive dyskinesia (TD) treatment progress by an Abnormal Involuntary Movement Scale (AIMS) score alone.
In this video, Craig Chepke, MD,...
05/12/2026
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Treating Beyond AIMS Scores: Tracking Functional Outcomes in Tardive Dyskinesia
05/12/2026
Craig Chepke, MD, DFAPA
In this video, Craig Chepke, MD, DFAPA, Chief Medical Officer, Psych Congress, discusses the pitfalls of evaluating tardive dyskinesia (TD) treatment progress by an Abnormal Involuntary Movement Scale (AIMS) score alone.
In this video, Craig Chepke, MD, DFAPA, Chief Medical Officer, Psych Congress, discusses the pitfalls of evaluating tardive dyskinesia (TD) treatment progress by an Abnormal Involuntary Movement Scale (AIMS) score alone.
In this video, Craig Chepke, MD,...
05/12/2026
Psych Congress Network
Brooke Kempf, PMHNP-BC
Videos
Navigating Anxiety, Pain, and Mixed Features in Depressive Disorders
04/16/2026
Brooke Kempf, MSN, PMHNP-BC
Psych Congress Steering Committee member Brooke Kempf, PMHNP-BC, offers clinicians a practical framework for differentiating overlapping symptoms, anxious distress, and mixed features in MDD.
Psych Congress Steering Committee member Brooke Kempf, PMHNP-BC, offers clinicians a practical framework for differentiating overlapping symptoms, anxious distress, and mixed features in MDD.
Psych Congress Steering...
04/16/2026
Psych Congress Network
Philip Gehrman, PhD, CBSM, FAASM
Videos
Targeting Sleep to Improve Mental Health Outcomes
04/08/2026
Philip Gehrman, PhD
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Psych Congress Steering...
04/08/2026
Psych Congress Network

From the Newsrooms

Craig Chepke and Kevin Williams
Major Depressive Disorder Insights
Anhedonia in MDD: What to Ask When Visit Time Is Short
07/07/2026
Craig Chepke, MD, DFAPA; Kevin Williams, MS, MPAS, PA-C
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how busy outpatient clinicians can effectively screen for anhedonia in major depressive disorder.
Craig Chepke, MD, DFAPA, and Kevin Williams, MS, MPAS, PA-C, discuss how busy outpatient clinicians can effectively screen for anhedonia in major depressive disorder.
Craig Chepke, MD, DFAPA, and...
07/07/2026
Psych Congress Network
psilocybin mushrooms in a beaker
Conference Coverage
Clinicians Prepared for Evolving Psychedelic Landscape at Psych Congress Elevate
06/06/2026
Maria Mantas
Experts at Elevate examined the evolving role of psychedelics in mental health care, highlighting emerging research, clinical considerations, and questions around access and safety.
Experts at Elevate examined the evolving role of psychedelics in mental health care, highlighting emerging research, clinical considerations, and questions around access and safety.
Experts at Elevate examined the...
06/06/2026
Psych Congress Network
Kids ride their bikes down a dirt path in a grassy field
Conference Coverage
d-ATS Shows Broad ADHD Efficacy in Pediatric Subgroups
06/06/2026
Brionna Mendoza
A poster presented at the 2026 Psych Congress Elevate reported that the dextroamphetamine transdermal system (d-ATS) was broadly effective for treating attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
A poster presented at the 2026 Psych Congress Elevate reported that the dextroamphetamine transdermal system (d-ATS) was broadly effective for treating attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
A poster presented at the 2026...
06/06/2026
Psych Congress Network
B. Nilaja Green, PhD
Q&As
Strengthening Interdisciplinary Collaboration in Mental Health Treatment
06/05/2026
B. Nilaja Green, PhD
B. Nilaja Green, PhD, reviews how psychiatric providers and psychotherapists can ensure they are aligned on patient treatment progress and goals.
B. Nilaja Green, PhD, reviews how psychiatric providers and psychotherapists can ensure they are aligned on patient treatment progress and goals.
B. Nilaja Green, PhD, reviews...
06/05/2026
Psych Congress Network
AI chatbot
Conference Coverage
AI Chatbot Risks Take Center Stage at Psych Congress Elevate
06/05/2026
Brionna Mendoza
Steven Chan, MD, and Andrew Gleim, PsyD, presented a session on navigating patient use of AI chatbots at the 10th Annual Psych Congress Elevate.
Steven Chan, MD, and Andrew Gleim, PsyD, presented a session on navigating patient use of AI chatbots at the 10th Annual Psych Congress Elevate.
Steven Chan, MD, and Andrew...
06/05/2026
Psych Congress Network
Veronica Ridpath, DO
Q&A
Advancing Autism Care in Psychiatric Practice
06/05/2026
Veronica Ridpath, DO
Veronica Ridpath, DO. discusses key considerations for diagnosing and supporting patients with autism spectrum disorder (ASD) in psychiatric practice.
Veronica Ridpath, DO. discusses key considerations for diagnosing and supporting patients with autism spectrum disorder (ASD) in psychiatric practice.
Veronica Ridpath, DO. discusses...
06/05/2026
Psych Congress Network
A black man sits in front of a computer looking frustrated with cognitive impairment trouble thinking major depressive disorder
Conference Coverage
Patients Indicate Cognitive Impairment Improvement as High Priority in MDD Treatment
06/03/2026
Brionna Mendoza
Research presented at the 10th annual Psych Congress Elevate underscores the prevalence of cognitive impairment in MDD and highlights patients’ desire to resolve the symptom.
Research presented at the 10th annual Psych Congress Elevate underscores the prevalence of cognitive impairment in MDD and highlights patients’ desire to resolve the symptom.
Research presented at the 10th...
06/03/2026
Psych Congress Network
Philip Gehrman, PhD, CBSM, FAASM
Videos
Targeting Sleep to Improve Mental Health Outcomes
04/08/2026
Philip Gehrman, PhD
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Psych Congress Steering Committee Partner Philip Gehrman, PhD, CBSM, FAASM, discusses how targeting sleep may improve outcomes for patients with co-occurring sleep and psychiatric disorders.
Psych Congress Steering...
04/08/2026
Psych Congress Network
Kristian Dambrino, DNP, PMHNP-BC
Conference Insights
Considerations for Selecting an Antidepressant in Major Depressive Disorder
03/27/2026
Kristian Dambrino, DNP, APRN, MSN
Kristian Dambrino, DNP, PMHNP-BC, shares practical, patient-centered strategies for selecting antidepressants in major depressive disorder (MDD).
Kristian Dambrino, DNP, PMHNP-BC, shares practical, patient-centered strategies for selecting antidepressants in major depressive disorder (MDD).
Kristian Dambrino, DNP,...
03/27/2026
Psych Congress Network
a white jigsaw puzzle of a brain against an orange background with one puzzle piece missing
News
AMPA Receptor Modulation Shows Promise in Major Depressive Disorder Treatment
03/24/2026
Brionna Mendoza
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP Institute highlights α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulation as a promising therapeutic target.
Research presented at NP...
03/24/2026
Psych Congress Network

Quizzes

an illustrated laptop screen displaying a quiz
Quiz
Patient Priorities in MDD Treatment
07/13/2026
Maria Mantas
Can you recall which symptom of MDD patients most wanted to see improved by treatment? Take the quiz!
Can you recall which symptom of MDD patients most wanted to see improved by treatment? Take the quiz!
Can you recall which symptom of...
07/13/2026
Psych Congress Network
Viloxazine MOA Study image
Quiz
Test Your Knowledge: New Study Clarifies Multimodal Mechanism of Viloxazine in ADHD
06/12/2026
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that viloxazine has a multimodal mechanism of action. Test your understanding with this short quiz.
New research suggests that...
06/12/2026
Psych Congress Network
Weight scale and tape measure
Quiz
Test Your Knowledge: Retrospective Cohort Study Explores Long-Term Growth Outcomes Following Pediatric Methylphenidate Use
06/12/2026
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the relationship between pediatric attention-deficit/hyperactivity disorder, methylphenidate use in childhood, and growth outcomes in adulthood? Test your knowledge with this short, multiple-choice quiz.
How well do you understand the...
06/12/2026
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Psilocybin Outcomes for MDD
06/11/2026
Brionna Mendoza
Test your knowledge of recent research with this quiz!
Test your knowledge of recent research with this quiz!
Test your knowledge of recent...
06/11/2026
Psych Congress Network
Desiree Matthews, PMHNP-BC
Quiz
Drug-Drug Considerations in TD Treatment
06/10/2026
Maria Mantas
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews,...
06/10/2026
Psych Congress Network
Desiree Matthews, PMHNP-BC
Quiz
Drug-Drug Considerations in TD Treatment
06/10/2026
Maria Mantas
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews, PMHNP-BC, recommend careful consideration of metabolic pathways when selecting a vesicular monoamine transporter 2 (VMAT2) inhibitor for tardive dyskinesia (TD) treatment?
Why does Desiree Matthews,...
06/10/2026
Psych Congress Network
Girl in a classroom staring off into the distance
Quiz
Test Your Knowledge – Beyond the Stereotype: Rethinking Sex Differences in ADHD Presentation
05/12/2026
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation between males and females may affect diagnosis and outcomes. Evaluate your understanding of key clinical distinctions with this short quiz.
Differences in ADHD presentation...
05/12/2026
Psych Congress Network
A boy eating junk food while using a laptop computer
Quiz
Test Your Knowledge: The Link Between Ultra-Processed Foods and ADHD
05/12/2026
How well do you understand the emerging evidence linking ultra-processed foods and ADHD? Assess your knowledge with this brief quiz.
How well do you understand the emerging evidence linking ultra-processed foods and ADHD? Assess your knowledge with this brief quiz.
How well do you understand the...
05/12/2026
Psych Congress Network
Nishi Bhopal, MD
Quiz
First Steps in Identifying Excessive Daytime Sleepiness
05/06/2026
Maria Mantas
What is the recommended first step to confirm whether a patient is experiencing excessive daytime sleepiness? Take this quick quiz to test your knowledge!
What is the recommended first step to confirm whether a patient is experiencing excessive daytime sleepiness? Take this quick quiz to test your knowledge!
What is the recommended first...
05/06/2026
Psych Congress Network
a printed test, pencil, and clock on a desk
Quiz
Mortality Risk in Bipolar II Disorder
04/30/2026
Maria Mantas
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between all-cause mortality risk and bipolar II disorder? Test your knowledge with this quiz!
What was the association between...
04/30/2026
Psych Congress Network

Recent FDA Updates

Food and Drug Administration building
News
FDA Approves Milsaperidone for Bipolar I and Schizophrenia in Adults
02/24/2026
Maria Mantas
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved...
02/24/2026
Psych Congress Network
US FDA building
News
FDA Requests Removal of Suicide Risk Warnings From GLP-1 RA Labels
01/14/2026
Maria Mantas
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug...
01/14/2026
Psych Congress Network
FDA building
News
FDA Approves At-Home Neuromodulation Therapy Device for Major Depression
01/12/2026
Maria Mantas
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Proliv™Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug...
01/12/2026
Psych Congress Network
FDA approval stamp
News
FDA Approves First At-Home tDCS Treatment for Major Depressive Disorder
12/16/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug...
12/16/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Lumateperone Indication for Major Depressive Disorder
11/07/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug...
11/07/2025
Psych Congress Network

Live Meetings

Psych Congress Family & Friends Podcast

Rakesh Jain and Craig Chepke
Podcasts
Psych Congress Family & Friends Podcast, Episode 8: Beyond the Headlines: The Good, The Bad, and The Ugly of SSRIs
10/09/2025
Rakesh Jain, MD, MPH, RD; Craig Chepke, MD, DFAPA; Ragy R. Girgis, MD, MS
In this episode, Drs Rakesh Jain and Craig Chepke are joined by Dr Ragy Girgis of Columbia University to explore the small but important nuances around antidepressants, black box warnings, and violence risk in untreated psychosis.
In this episode, Drs Rakesh Jain and Craig Chepke are joined by Dr Ragy Girgis of Columbia University to explore the small but important nuances around antidepressants, black box warnings, and violence risk in untreated psychosis.
In this episode, Drs Rakesh Jain...
10/09/2025
Psych Congress Network
Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 7: Sleep is the Foundation of Mental Health
09/12/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
Sleep–wake disorders are clinically significant and too often overlooked in psychiatric practice. Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating insomnia, hypersomnia, and obstructive sleep apnea.
Sleep–wake disorders are clinically significant and too often overlooked in psychiatric practice. Drs. Rakesh Jain and Craig Chepke share practical strategies for recognizing and treating insomnia, hypersomnia, and obstructive sleep apnea.
Sleep–wake disorders are...
09/12/2025
Psych Congress Network
Rakesh Jain and Craig Chepke
Podcasts
Psych Congress Family & Friends Podcast, Episode 6: Psychiatry Is the Specialty That Speaks for Those Without a Voice
09/08/2025
Rakesh Jain, MD, MPH, RD; Craig Chepke, MD, DFAPA
In this episode, Drs Rakesh Jain and Craig Chepke explore why fibromyalgia belongs in psychiatry’s wheelhouse and address the stigma patients face every day.
In this episode, Drs Rakesh Jain and Craig Chepke explore why fibromyalgia belongs in psychiatry’s wheelhouse and address the stigma patients face every day.
In this episode, Drs Rakesh Jain...
09/08/2025
Psych Congress Network
Craig Chepke and Rakesh Jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 5: We’re Too Addicted to Our Own Good Ideas
08/25/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain and Craig Chepke reflect on how the words we use—and the habits we form—shape the way we practice. The pair also take a fresh look at the serotonin story, talk through new ways of understanding depression, and...
In this episode, Drs Rakesh Jain...
08/25/2025
Psych Congress Network
craig chepke and rakesh jain
Podcasts
Psych Congress Family & Friends Podcast, Episode 4: Every Pill is a Choice
07/25/2025
Craig Chepke, MD, DFAPA; Rakesh Jain, MD, MPH, RD
Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in front of us.
Through a positive psychiatry lens, Drs Rakesh Jain and Craig Chepke reflect on recent research, the challenges of psychiatric diagnosis, and why every treatment decision should begin with a deep understanding of the person in front of us.
Through a positive psychiatry...
07/25/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, MSN, APRN, PMHNP-BC
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Insights
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use